Evidence map›Paper›PMID 28322926›Full record

ArticleBiochimie2017

Caffeine inhibition of GLUT1 is dependent on the activation state of the transporter.

Leesha K Gunnink, Brianna M Busscher, Jeremy A Wodarek, Kylee A Rosette, Lauren E Strohbehn, Brendan D Looyenga, Larry L Louters

Abstract read
In one paragraph

Article in Biochimie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Direct targeting of GLUT1 in cancer: A decade of inhibitor discovery and medicinal chemistry insights.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Review
  3. Review
  4. Erythroid glucose transport in health and disease.Pflugers Archiv : European journal of physiology · 2020
    Review
  5. Article
  6. Article
  7. [Monocarboxylate transporter 1 enhances the sensitivity of breast cancer cells to 3-bromopyruvate in vitro].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Leesha K GunninkDepartment of Chemistry and Biochemistry, Calvin College, Grand Rapids, MI 49546, USA.
Brianna M BusscherDepartment of Chemistry and Biochemistry, Calvin College, Grand Rapids, MI 49546, USA.
Jeremy A WodarekDepartment of Chemistry and Biochemistry, Calvin College, Grand Rapids, MI 49546, USA.
Kylee A RosetteDepartment of Chemistry and Biochemistry, Calvin College, Grand Rapids, MI 49546, USA.
Lauren E StrohbehnDepartment of Chemistry and Biochemistry, Calvin College, Grand Rapids, MI 49546, USA.
Brendan D LooyengaDepartment of Chemistry and Biochemistry, Calvin College, Grand Rapids, MI 49546, USA.
Larry L LoutersDepartment of Chemistry and Biochemistry, Calvin College, Grand Rapids, MI 49546, USA. Electronic address: lout@calvin.edu.
Calvin University · US

Funding

The Mechanism for the Acute Activation of GLUT1R15DK081931 · NIDDK · CALVIN UNIVERSITY · PI LOUTERS, LAURENCE LEON · 2009 to 2014
$600k
NIDDK NIH HHS R15 DK081931
6 · The paper itself

Abstract

Caffeine has been shown to be a robust uncompetitive inhibitor of glucose uptake in erythrocytes. It preferentially binds to the nucleotide-binding site on GLUT1 in its tetrameric form and mimics the inhibitory action of ATP. Here we demonstrate that caffeine is also a dose-dependent, uncompetitive inhibitor of 2-deoxyglucose (2DG) uptake in L929 fibroblasts. The inhibitory effect on 2DG uptake in these cells was reversible with a rapid onset and was additive to the competitive inhibitory effects of glucose itself, confirming that caffeine does not interfere with glucose binding. We also report for the first time that caffeine inhibition was additive to inhibition by curcumin, suggesting distinct binding sites for curcumin and caffeine. In contrast, caffeine inhibition was not additive to that of cytochalasin B, consistent with previous data that reported that these two inhibitors have overlapping binding sites. More importantly, we show that the magnitude of maximal caffeine inhibition in L929 cells is much lower than in erythrocytes (35% compared to 90%). Two epithelial cell lines, HCLE and HK2, have both higher concentrations of GLUT1 and increased basal 2DG uptake (3-4 fold) compared to L929 cells, and subsequently display greater maximal inhibition by caffeine (66-70%). Interestingly, activation of 2DG uptake (3-fold) in L929 cells by glucose deprivation shifted the responsiveness of these cells to caffeine inhibition (35%-70%) without a change in total GLUT1 concentration. These data indicate that the inhibition of caffeine is dependent on the activity state of GLUT1, not merely on the concentration.

Indexed as

Biological TransportBlotting, WesternCaffeineCentral Nervous System StimulantsCytochalasin BDeoxyglucoseEpithelial CellsErythrocytesFibroblastsGene Expression RegulationGlucose Transporter Type 1HumansSignal TransductionCaffeineCentral Nervous System StimulantsCytochalasin BDeoxyglucoseGlucose Transporter Type 1SLC2A1 protein, humanCaffeineCurcuminGlucose uptakeGLUT1L929 fibroblast

Identifiers

PMID28322926
PMCPMC6141003
OpenAlexW2596504500

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.